openPR Logo
Press release

In Depth Research on Global Controlled Drug Delivery Market and Clinical Trial Outlook 2022

10-03-2017 11:06 AM CET | Health & Medicine

Press release from: KuicK Research

In Depth Research on Global Controlled Drug Delivery Market

“Global Controlled Drug Delivery Market and Clinical Trial Outlook 2022” report highlights:

* Evolution and Fundamentals of Controlled Drug Delivery
* Mode of Action and Approaches of Controlled Drug Delivery
* Global Controlled Release Drug Market Overview
* Insight on Global Controlled Release Drug Clinical Pipeline
* Clinical Insight on 303 Controlled Release Drug in Clinical Trials
* Clinical, Patent and Technology insight of 133 Marketed Controlled Release Drugs
* Controlled Release Drug Market Future Outlook

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-controlled-drug-delivery-market-and-clinical-trial-outlook-2022.php

Table of Contents

1 Drug Delivery: An Advancing Trajectory
1.1 Preface Towards Drug Delivery
1.2 Idealism of Drug Delivery System

2. Introduction to Controlled Drug Delivery
2.1 Novel Drug Delivery Systems
2.2 Preamble to Controlled Drug Delivery

3. Evolution of Controlled Drug Delivery
3.1 First Generation
3.2 Second Generation

4. Fundamentals of Controlled Drug Delivery
4.1 Prerequisites of Controlled Delivery
4.2 Rationale for Controlled Drug Delivery

5. Mechanism of Controlled Drug Release
5.1 Diffusion Controlled
5.2 Dissolution Controlled System
5.3 Water Penetration Controlled System
5.4 Erosion Controlled System
5.5 Ion-Exchange Controlled System

6. Cataloging of Controlled Drug Delivery
6.1 Classification Based Over Delivery Systems
6.2 Classification Based Over Technicality
6.3 Classification Based Over Routes

7. Approaches for Controlled Drug Delivery
7.1 Polymers
7.2 Chronopharmaceutics
7.3 Nanoparticulate Delivery System

8. Global Controlled Release Drug Clinical Pipeline Overview
8.1 Phase
8.2 Country/Region
8.3 Mode of Action
8.4 Drug class
8.5 Indication

9. Application of Controlled Drug Delivery
9.1 Diabetes
9.2 Cancer
9.3 Cardiovascular Diseases
9.4 Neurological Disorders
9.5 Infections

10. Drug Designing for Controlled Delivery
10.1 Enteral Dosage Formulations
10.1.1 Solid Dosage Forms
10.1.2 Liquid Dosage Forms
10.1.3 Inhalation Dosage Forms
10.2 Parenteral Dosage Forms
10.2.1 Injectable Dosage Forms
10.2.2 Implantable Device
10.3 General Mechanisms of Drug Release

11. Market Inclinations
11.1 Market over Routes of Administration
11.2 Market over Approaches

12. Global Controlled Drug Delivery Market Dynamics
12.1 Accelerative Parameters
12.2 Challenges

13. Global Controlled Drug Delivery Market Future Outlook
13.1 Ongoing Clinical Trials
13.2 Future Market Opportunities

14. Global Controlled Drug Delivery Clinical Trials by Company, Indication and Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered

15. Marketed Controlled Release Clinical Insight by Company, Indication and Phase

16. Competitive Landscape
16.1 Allergan
16.2 Amylin Pharmaceuticals
16.3 AstraZeneca
16.4 BioAlliance Pharma
16.5 Biogen
16.6 Collegium Pharmaceutical
16.7 Controlled Therapeutics (Ferring Pharmaceuticals)
16.8 Cosmo Pharmaceuticals
16.9 Egalet
16.10 Elan Corporation
16.11 Encore Therapeutics
16.12 Flamel Technologies
16.13 GlaxoSmithKline
16.14 Heron Therapeutics
16.15 iCeutica
16.16 Mithra Pharmaceuticals
16.17 Neurim Pharmaceuticals
16.18 Novartis
16.19 Orexigen Therapeutics
16.20 Otsuka Pharmaceutical
16.21 Pfizer
16.22 Purdue Pharma
16.23 Syntex Pharmaceuticals International
16.24 Takeda
16.25 Zealand Pharma

Figure 1-1: Characteristics of an Ideal drug Delivery System
Figure 2-1: Limitations of the Conventional Drug Delivery Systems
Figure 2-2: Diversification of the Novel Drug Delivery Platforms
Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 4-1: Demonstration of the Targeted and Non-Targeted Drug Delivery
Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 6-1: Plasma Concentration v/s Time Profile in Conventional and Controlled Release
Figure 6-2: Comparison of Varied Modified Drug Release Systems
Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 6-4: Classification Based Over the Technicality Erudition
Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
Figure 6-6: Classification Based over the Route of Administration
Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2017 till 2022
Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2017 till 2022
Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2017 till 2022
Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2017 till 2022
Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2017 till 2022
Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2017 till 2022
Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
Figure 10-3: Representation of Categories of Liquid Dosage Form
Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
Figure 10-5: General Forms of Oral Controlled Release System Mechanism
Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
Figure 11-1: Drug Delivery Share by Route of Administration, 2016
Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2016 and 2022
Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2016 and 2022
Figure 11-4: Global - Implantable Device Market (US$ Billion), 2016 and 2022
Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2016 and 2022
Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2016 and 2022
Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2016 and 2022
Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2016-2022
Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release In Depth Research on Global Controlled Drug Delivery Market and Clinical Trial Outlook 2022 here

News-ID: 751574 • Views: 100

More Releases from KuicK Research

Stem Cell Therapy Revolutionizing Conventional Therapy Market
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
Cell Therapy to Transform Immuno Oncology Landscape
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025
"US Breast Cancer Drug Market, Price, Dosage and Clinical Pipeline Insight 2025" Report Highlights: US Breast Cancer Drug Market Opportunity: US$ 20 Billion US Breast Cancer Drug Clinical Pipeline by Company, Phase, Drug Class and Patient Segment US Breast Cancer Marketed Drugs: 42 Drugs US Breast Cancer Drug Clinical Pipeline: 317 Drugs Dosage and Pricing Insight for Preventive and Treatment Drugs US Breast Cancer Drug Market Dynamics For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Download Report:
Download Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportun …
"Global Cell Therapy Market, Clinical Trials, Therapy Price and Opportunity Insight 2026" Report Highlights: Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 Cell Therapy Clinical Trial Insight by Indication, Company and Country Global Cell Therapy Clinical Pipeline: 767 Cell Therapies Globally Marketed Cell Therapies: 25 Cell Therapies Maximum Number of Marketed Cell Therapies In USA: 15 Therapies Price and Product Insight By Region/Country Regional Analysis of the Cell Therapy Market

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning